Post-marketing observational safety study of durvalumab in Japanese patients with unresectable stage III NSCLC (PACIFIC regimen)

Terufumi Kato,Masahiro Endo,Yoshinobu Saito,Tomohisa Baba, Kayoko Tsujino, Keiko Shibuya,Yutaka Fujiwara,Hirotsugu Kenmotsu,Katsunori Oikado, Kei Sakamoto,Masahiro Nii, Mariko Hotta, Yuka Noda,Toshimitsu Tokimoto,Fumikazu Sakai, Masahiko Kusumoto

ANNALS OF ONCOLOGY（2023）

引用 0|浏览9

暂无评分

摘要

Durvalumab is the global standard-of-care for the consolidation treatment of locally-advanced, unresectable NSCLC following definitive chemoradiotherapy based on the results of the PACIFIC trial. Since interstitial lung disease/radiation pneumonitis (ILD/RP) was more frequently observed in Japanese patients (73.6%) than seen globally (33.9%) in the PACIFIC trial, safety including ILD/RP risk was assessed in a post-marketing study.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要